NCT05631886View on ClinicalTrials.gov

Combination of CAR-DC Vaccine and ICIs in Malignant Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

July 4, 2023

Primary Completion Date

December 30, 2025

Study Completion Date

December 30, 2026

Conditions
Solid Tumor, AdultLymphomaEphA2 OverexpressionTP53 R273HTP53 R175HTP53 R248QTP53 R249S
Interventions
BIOLOGICAL

TP53-EphA-2-CAR-DC

5\~10 × 10\^6 CAR DCs per dose will be administered by intravenous injection.

DRUG

Abraxane

Intravenous abraxane 125 mg/m\^2/day on day-5.

DRUG

Cyclophosphamide

Intravenous cyclophosphamide 300 mg/m\^2/day on day -4.

DRUG

anti-PD-1 antibody

Intravenous anti-PD-1 antibody 200 mg/day.

DRUG

Anti-CTLA4 Monoclonal Antibody

Intravenous anti-CTLA4 antibody 1 mg/kg/day

Trial Locations (1)

100853

RECRUITING

Biotherapeutic Department of Chinsese PLA Gereral Hospital, Beijing

All Listed Sponsors
collaborator

Zhejiang University

OTHER

lead

Chinese PLA General Hospital

OTHER